111In- and 90Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial: Radiolabeled peptides in diagnoses and therapy

111In- and 90Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial: Radiolabeled peptides in diagnoses and therapy

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Seminars in nuclear medicine 2002, Vol.32 (2), p.148-155
Hauptverfasser: VIRGOLINI, Irene, BRITTON, Keith, BUSCOMBE, John, MONCAYO, Roy, PAGANELLI, Giovanni, RIVA, Pietro
Format: Artikel
Sprache:eng
Schlagworte:
Biological and medical sciences
Medical sciences
Radiation therapy and radiosensitizing agent
Treatment with physical agents
Treatment. General aspects
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 155
container_issue 2
container_start_page 148
container_title Seminars in nuclear medicine
container_volume 32
creator VIRGOLINI, Irene
BRITTON, Keith
BUSCOMBE, John
MONCAYO, Roy
PAGANELLI, Giovanni
RIVA, Pietro
description
format Article
fullrecord <record><control><sourceid>pascalfrancis</sourceid><recordid>TN_cdi_pascalfrancis_primary_13611728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>13611728</sourcerecordid><originalsourceid>FETCH-pascalfrancis_primary_136117283</originalsourceid><addsrcrecordid>eNqNyk0LgjAYAOARBdnHf9il42CbzbSb9EEeQjA9dJIXnbSYU7Z16N8H0Q_o9FyeCQqYEDHZRjycooBSyghPkniOFs49KeVCJCJAOWMsMwSDaXFC7-SYlynRYKwcvGrlHhfSvbR336D6UasGvBqMw0OH_UPia1oVWZlVN-ytAr1Csw60k-ufS7Q5n8rDhYzgGtCdBdMoV49W9WDfNQsjxnY8Dv99H5CHPwo</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>111In- and 90Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial: Radiolabeled peptides in diagnoses and therapy</title><source>ScienceDirect Freedom Collection (Elsevier)</source><creator>VIRGOLINI, Irene ; BRITTON, Keith ; BUSCOMBE, John ; MONCAYO, Roy ; PAGANELLI, Giovanni ; RIVA, Pietro</creator><creatorcontrib>VIRGOLINI, Irene ; BRITTON, Keith ; BUSCOMBE, John ; MONCAYO, Roy ; PAGANELLI, Giovanni ; RIVA, Pietro</creatorcontrib><identifier>ISSN: 0001-2998</identifier><identifier>EISSN: 1558-4623</identifier><identifier>CODEN: SMNMAB</identifier><language>eng</language><publisher>New York, NY: Elsevier</publisher><subject>Biological and medical sciences ; Medical sciences ; Radiation therapy and radiosensitizing agent ; Treatment with physical agents ; Treatment. General aspects ; Tumors</subject><ispartof>Seminars in nuclear medicine, 2002, Vol.32 (2), p.148-155</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4022</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13611728$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>VIRGOLINI, Irene</creatorcontrib><creatorcontrib>BRITTON, Keith</creatorcontrib><creatorcontrib>BUSCOMBE, John</creatorcontrib><creatorcontrib>MONCAYO, Roy</creatorcontrib><creatorcontrib>PAGANELLI, Giovanni</creatorcontrib><creatorcontrib>RIVA, Pietro</creatorcontrib><title>111In- and 90Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial: Radiolabeled peptides in diagnoses and therapy</title><title>Seminars in nuclear medicine</title><subject>Biological and medical sciences</subject><subject>Medical sciences</subject><subject>Radiation therapy and radiosensitizing agent</subject><subject>Treatment with physical agents</subject><subject>Treatment. General aspects</subject><subject>Tumors</subject><issn>0001-2998</issn><issn>1558-4623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqNyk0LgjAYAOARBdnHf9il42CbzbSb9EEeQjA9dJIXnbSYU7Z16N8H0Q_o9FyeCQqYEDHZRjycooBSyghPkniOFs49KeVCJCJAOWMsMwSDaXFC7-SYlynRYKwcvGrlHhfSvbR336D6UasGvBqMw0OH_UPia1oVWZlVN-ytAr1Csw60k-ufS7Q5n8rDhYzgGtCdBdMoV49W9WDfNQsjxnY8Dv99H5CHPwo</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>VIRGOLINI, Irene</creator><creator>BRITTON, Keith</creator><creator>BUSCOMBE, John</creator><creator>MONCAYO, Roy</creator><creator>PAGANELLI, Giovanni</creator><creator>RIVA, Pietro</creator><general>Elsevier</general><scope>IQODW</scope></search><sort><creationdate>2002</creationdate><title>111In- and 90Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial</title><author>VIRGOLINI, Irene ; BRITTON, Keith ; BUSCOMBE, John ; MONCAYO, Roy ; PAGANELLI, Giovanni ; RIVA, Pietro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pascalfrancis_primary_136117283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biological and medical sciences</topic><topic>Medical sciences</topic><topic>Radiation therapy and radiosensitizing agent</topic><topic>Treatment with physical agents</topic><topic>Treatment. General aspects</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VIRGOLINI, Irene</creatorcontrib><creatorcontrib>BRITTON, Keith</creatorcontrib><creatorcontrib>BUSCOMBE, John</creatorcontrib><creatorcontrib>MONCAYO, Roy</creatorcontrib><creatorcontrib>PAGANELLI, Giovanni</creatorcontrib><creatorcontrib>RIVA, Pietro</creatorcontrib><collection>Pascal-Francis</collection><jtitle>Seminars in nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VIRGOLINI, Irene</au><au>BRITTON, Keith</au><au>BUSCOMBE, John</au><au>MONCAYO, Roy</au><au>PAGANELLI, Giovanni</au><au>RIVA, Pietro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>111In- and 90Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial: Radiolabeled peptides in diagnoses and therapy</atitle><jtitle>Seminars in nuclear medicine</jtitle><date>2002</date><risdate>2002</risdate><volume>32</volume><issue>2</issue><spage>148</spage><epage>155</epage><pages>148-155</pages><issn>0001-2998</issn><eissn>1558-4623</eissn><coden>SMNMAB</coden><cop>New York, NY</cop><pub>Elsevier</pub></addata></record>
fulltext fulltext
identifier ISSN: 0001-2998
ispartof Seminars in nuclear medicine, 2002, Vol.32 (2), p.148-155
issn 0001-2998
1558-4623
language eng
recordid cdi_pascalfrancis_primary_13611728
source ScienceDirect Freedom Collection (Elsevier)
subjects Biological and medical sciences
Medical sciences
Radiation therapy and radiosensitizing agent
Treatment with physical agents
Treatment. General aspects
Tumors
title 111In- and 90Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial: Radiolabeled peptides in diagnoses and therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T19%3A50%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pascalfrancis&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=111In-%20and%2090Y-DOTA-lanreotide:%20Results%20and%20implications%20of%20the%20MAURITIUS%20trial:%20Radiolabeled%20peptides%20in%20diagnoses%20and%20therapy&rft.jtitle=Seminars%20in%20nuclear%20medicine&rft.au=VIRGOLINI,%20Irene&rft.date=2002&rft.volume=32&rft.issue=2&rft.spage=148&rft.epage=155&rft.pages=148-155&rft.issn=0001-2998&rft.eissn=1558-4623&rft.coden=SMNMAB&rft_id=info:doi/&rft_dat=%3Cpascalfrancis%3E13611728%3C/pascalfrancis%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true